Author(s):
Priyanka B. Varne, Ashok A. Hajare, Avadhut J. Gaikwad, Pournima S. Sankpal, Bhushan S. Varne, Hemlata S. Dol
Email(s):
ashok.hajare@bharatividyapeeth.edu
DOI:
10.52711/0974-360X.2026.00610 
Address:
Priyanka B. Varne1, Ashok A. Hajare2*, Avadhut J. Gaikwad1, Pournima S. Sankpal2, Bhushan S. Varne3, Hemlata S. Dol4
1Bharati Vidyapeeth College of Pharmacy, Kolhapur, Maharashtra, India 416013.
2Bharati Vidyapeeth College of Pharmacy, Palus, Maharashtra, India 416310.
3Sarojini College of Pharmacy, Kolhapur, Maharashtra, India 416004.
4Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Satara, 415539, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 9,
Year - 2026
ABSTRACT:
The BCS Class IV drug abiraterone acetate (ABR) exhibits biopharmaceutical difficulties including polymorphism, poor solubility (< 0.5 µg/mL), variable permeability, and low oral bioavailability (<10 %, necessitating a large dose of 1000 mg/day). The primary goal of the current study is to produce solid lipid nanoparticles (SLNs) that are loaded with ABR to improve solubility. SLNs were manufactured by O/W microemulsion method. Initial screening of lipids was done by solubility study whereas surfactants and co-surfactants were selected on the basis of their HLB values. Based on preformulation studies, Myristic acid, Tween 80 and PEG 400 were selected for SLN composition. Using Central Composite Design (CCD) experiments were conducted to optimize the composition using concentration of solid lipid and S-mix as independent variables while particle size, entrapment efficiency (EE), and zeta potential as independent variables. Optimized SLN formulation and pure drug were compared for in vitro drug release. Cytotoxicity study of optimized formulation was tested using MTT assay method. The statistical evaluation confirmed that optimized ABR-SLNs were spherical with average size of 194.26 nm, polydispersity index (PDI) of 0.491, EE of 89.56 %, and zeta potential of -23.77 mV. Drug release from optimized formulation over 6 h and cytotoxicity study demonstrated remarkable anticancer activity. It was observed that SLN shows significant improvement in the solubility of ABR. Hence, SLN can acts as drug delivery system for enhancing the solubility of poorly soluble drugs.
Cite this article:
Priyanka B. Varne, Ashok A. Hajare, Avadhut J. Gaikwad, Pournima S. Sankpal, Bhushan S. Varne, Hemlata S. Dol. Microemulsion-Mediated Abiraterone Acetate Nanoparticles: Formulation and Optimization. Research Journal Pharmacy and Technology. 2026;19(9):4369-8. doi: 10.52711/0974-360X.2026.00610
Cite(Electronic):
Priyanka B. Varne, Ashok A. Hajare, Avadhut J. Gaikwad, Pournima S. Sankpal, Bhushan S. Varne, Hemlata S. Dol. Microemulsion-Mediated Abiraterone Acetate Nanoparticles: Formulation and Optimization. Research Journal Pharmacy and Technology. 2026;19(9):4369-8. doi: 10.52711/0974-360X.2026.00610 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-9-56
REFERENCES:
1. Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, Rawla P, Barsouk A. Epidemiology, staging and management of prostate cancer. Medical sciences. 2020 Jul 20;8(3):28.
2. Vakili S, Beheshti I, Barzegar Behrooz A, Łos MJ, Vitorino R, Ghavami S. Transforming prostate cancer care: Innovations in diagnosis, treatment, and future directions. International Journal of Molecular Sciences. 2025 Jun 4;26(11):5386.
3. Batool S, Sohail S, ud Din F, Alamri AH, Alqahtani AS, Alshahrani MA, Alshehri MA, Choi HG. A detailed insight of the tumor targeting using nanocarrier drug delivery system. Drug Delivery. 2023 Dec 31;30(1):2183815.
4. Beg S, Malik AK, Ansari MJ, Malik AA, Ali AM, Theyab A, Algahtani M, Almalki WH, Alharbi KS, Alenezi SK, Barkat MA. Systematic development of solid lipid nanoparticles of abiraterone acetate with improved oral bioavailability and anticancer activity for prostate carcinoma treatment. ACS omega. 2022 May 24;7(20):16968-79.
5. Mehralitabar H, Ghasemi AS, Gholizadeh J. Abiraterone and D4, 3-keto Abiraterone binding to CYP17A1, a structural comparison study by molecular dynamic simulation. Steroids. 2021 Mar 1;167:108799.
6. Putchakayala NS, Morusu K, Ramisetty S, Ravoru N. Nanostructured lipid carriers: a novel platform in the formulation of targeted drug delivery systems. Current Nanomedicine. 2025 Feb;15(1):26-49.
7. Mohammed HA, Khan RA, Singh V, Yusuf M, Akhtar N, Sulaiman GM, Albukhaty S, Abdellatif AA, Khan M, Mohammed SA, Al-Subaiyel AM. Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers’ development. Nanotechnology reviews. 2023 Feb 18;12(1):20220517.
8. Ahmed S, Gozal D, Khalyfa A. nano-based vaccine delivery systems: Innovative therapeutics against cancer and neurological disorders. International Journal of Molecular Sciences. 2025 Oct 23;26(21):10316.
9. Bilia AR, Piazzini V, Risaliti L, Vanti G, Casamonti M, Wang M, Bergonzi MC. Nanocarriers: a successful tool to increase solubility, stability and optimise bioefficacy of natural constituents. Current medicinal chemistry. 2019 Jul 1;26(24):4631-56.
10. Yadav PS, Hajare AA, Dhole RS, Dharangutikar S. Exploring Cosolvency in Analytical Method Development and Validation of Poorly Aqueous Soluble Candesartan Cilexetil in Bulk and Dosage Forms. Indian Journal of Pharmaceutical Sciences. 2023 Mar 1;86(2):660-6.
11. Hanafy NA, Sheashaa RF, Moussa EA, Mahfouz ME. Potential of curcumin and niacin-loaded targeted chitosan coated liposomes to activate autophagy in hepatocellular carcinoma cells: an in vitro evaluation in HePG2 cell line. International journal of biological macromolecules. 2023 Aug 1;245:125572.
12. Yadav PS, Hajare AA, Patil KS. Development of Doxazosin mesylate liquisolid system for improved manufacturing processability and bioavailability: in vitro and in vivo evaluation for tailored hypertension treatment approach with modified dissolution rates. Journal of Dispersion Science and Technology. 2024 May 2;45(6):1227-40.
13. Chauhan I, Singh L. A comprehensive literature review of lipids used in the formulation of lipid nanoparticles. Current Nanomaterials. 2023 Aug 1;8(2):126-52.
14. Jana BK, Singha I, Puro N, Baishya R, Dutta RS, Singh M, Mazumder B. Pseudo-ternary phase diagram based PEGylated nano-dispersion of linezolid to promote wound regeneration: an in vitro and in vivo evaluation. Journal of Drug Targeting. 2025 Jul 3;33(6):989-1003.
15. Zou S, Ai H, Xie P, Lee YY, Huang Y, Pei HS, Xu M, Wang Y, Zhang Z. Design and mechanistic insights of diacylglycerol-based microemulsions for enhanced transdermal delivery: experimental optimization and molecular dynamics simulation. Journal of Colloid and Interface Science. 2025 Nov 4:139399.
16. Salabat A, Mirhoseini F. Polymer‐based nanocomposites fabricated by microemulsion method. Polymer Composites. 2022 Mar;43(3):1282-94.
17. Almalik A, Alradwan I, Kalam MA, Alshamsan A. Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating. Saudi pharmaceutical journal. 2017 Sep;25(6):861-7.
18. Varne PB, Hajare AA, Sankpal PS, Kamble SJ, Patil KS. Bosentan Solid Lipid Nanoparticle Development and Statistical Optimization Using 32 Full Factorial Design. Research Journal of Pharmacy and Technology. 2025;18(12):6101-9.
19. Thorat V, Tekade A. Design, Optimization, and In Vivo Evaluation of Mucoadhesive Nanostructured Lipid Carriers for Nose-to-Brain Delivery of Pramipexole in Parkinson’s Disease. Journal of Pharmaceutical Innovation. 2026 Aug;21(4):375.
20. Darwish A, Sándor N, Szenti I, Marosvölgyi T, Juhász K, Rónavári A, Kachal E, Kutus B, Kónya Z, Balogi Z. Highly stable antitumor silver-lipid nanoparticles optimized for targeted therapy. International Journal of Nanomedicine. 2025 Dec 31:1351-66.
21. Sankpal P, Mane S, Pathak R, Yasmeen A, Binshaya AS. Design, Optimization and Physicochemical Characterization of Pectin-Based Nanoparticles for In-vitro Anticancer Evaluation Against HCT116 Colon Cancer Cells. Current Pharmaceutical Design, 2026.
22. Yadav PS, Hajare AA, Patil KS. Design and development of Fujicalin-based axitinib liquisolid compacts for improved dissolution and bioavailability to treat renal cell carcinoma. European Journal of Pharmaceutics and Biopharmaceutics. 2024; 204:114506.
23. Rana H, Khambholja V, Thakkar V, Gadhvi V, Rabari P, Gandhi T. Refining the performance of Abiraterone Acetate through industry-friendly techniques for improving functionality. Ars Pharmaceutica (Internet). 2025 Sep 19;66(4):412-25.
24. Patil P, Bhagwat P, Sankpal P, Patil S, Dhawale S. Formulation and evaluation of transdermal niosomal gel for antihyperlipidemic agent. Nanoscience & Nanotechnology-Asia. 2024 Apr 1;14(2):88-97.
25. Jalilian M, Derakhshandeh K, Kurd M, Lashani H. Targeting solid lipid nanoparticles with anisamide for docetaxel delivery to prostate cancer: preparation, optimization, and in-vitro evaluation. Iranian Journal of Pharmaceutical Research: IJPR. 2021;20(1):327.